Garg Pushkal 4

What Happened
Garg Pushkal, Executive Vice President & Chief R&D Officer at Alnylam Pharmaceuticals, sold a total of 4,713 shares of ALNY common stock in open-market transactions on March 4–5, 2026. Sales were executed at prices ranging approximately from $319.03 to $326.08, generating aggregate proceeds of about $1,524,795. Several sales were automatic “sell‑to‑cover” transactions to satisfy tax withholding on vested RSUs; some sales were executed pursuant to a previously adopted Rule 10b5‑1 trading plan.

Key Details

• Transaction dates: March 4 and March 5, 2026. Prices reported ranged roughly $319.03–$326.08 (some entries are weighted averages across multiple trades).
• Total shares sold: 4,713. Total proceeds: ≈ $1.525 million.
• Shares owned after the transaction: Not specified in the provided filing data.
• Notable footnotes: F1 indicates mandatory sell‑to‑cover for tax withholding; F10 notes a Rule 10b5‑1 plan; several F11–F14 footnotes indicate weighted‑average prices across multiple sales.
• Transaction code: S = Sale.
• Timeliness: Filing dated March 6, 2026 for trades on March 4–5, 2026 — appears to be filed within the usual two‑business‑day Form 4 window.

Context
These transactions include routine sell‑to‑cover activity tied to RSU vesting and planned sales under a 10b5‑1 program. Such sales are generally considered routine and do not, by themselves, indicate management’s view on the company’s near‑term prospects. As always, investors should consider insider activity alongside other company and market information.